RICHMOND, Va.--(BUSINESS WIRE)--Insmed Inc. (Nasdaq:INSM), a biopharmaceutical company focused on the development of drug candidates for the treatment of metabolic diseases and endocrine disorders with unmet medical needs, today announced results for the three month period ended March 31, 2007.
